(Q34636518)

English

Preclinical rationale for combining an EGFR antibody with cisplatin/gemcitabine for the treatment of NSCLC.

scientific article

In more languages
default for all languages
No label defined

No description defined

Statements

Preclinical rationale for combining an EGFR antibody with cisplatin/gemcitabine for the treatment of NSCLC (English)

Identifiers

 
edit
    edit
      edit
        edit
          edit
            edit
              edit
                edit
                  edit